Transgene News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

07.11.24	Transgene Reports Business, Pipeline and Financial Update for Q3 2024 (GlobeNewswire)
07.11.24	Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024 (GlobeNewswire)
05.11.24	Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development (GlobeNewswire)
14.10.24	Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers (GlobeNewswire)
07.10.24	Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024 (GlobeNewswire)
24.09.24	2024 Half-Year Financial Report (GlobeNewswire)
24.09.24	Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025 (GlobeNewswire)
24.09.24	Availability of Transgene’s Half-Year Financial Report as of June 30, 2024 (GlobeNewswire)
14.09.24	Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments (GlobeNewswire)
10.09.24	Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation (GlobeNewswire)
09.09.24	Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024 (GlobeNewswire)
05.09.24	Transgene to Participate in HTID Conference and Investor Access Forum in Paris (GlobeNewswire)
27.08.24	Transgene — Preclinical Proof-of-Concept Data of Oncolytic Virus TG6050 published in JITC (GlobeNewswire)
22.07.24	Transgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024 (GlobeNewswire)
10.07.24	Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30, 2024 (GlobeNewswire)
03.06.24	Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer (GlobeNewswire)
15.05.24	Transgene’s Combined General Meeting of May 15, 2024 (GlobeNewswire)
14.05.24	Transgene provides business and financial update for Q1 2024 (GlobeNewswire)
24.04.24	Availability of Preparatory Documents for the Combined General Meeting of May 15, 2024 (GlobeNewswire)
11.04.24	Availability of Transgene's 2023 Universal Registration Document (GlobeNewswire)
09.04.24	Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024 (GlobeNewswire)
27.03.24	Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025 (GlobeNewswire)
27.03.24	Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer (GlobeNewswire)
18.03.24	Transgene Announces Upcoming Investor Meetings (GlobeNewswire)
06.03.24	Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024 (GlobeNewswire)
05.03.24	Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050 (GlobeNewswire)
22.01.24	Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer (GlobeNewswire)
22.01.24	Transgene Announces Financial Calendar for 2024 (GlobeNewswire)
08.01.24	Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050 (GlobeNewswire)
04.01.24	Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2023 (GlobeNewswire)
21.12.23	Transgene Announces Upcoming Investor Meetings (Businesswire)
05.12.23	Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy (Businesswire)
07.11.23	Transgene Reports Business Update and Q3 2023 Financial Position (Businesswire)
10.10.23	Transgene and BioInvent - First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA® (pembrolizumab) (Businesswire)
20.09.23	Transgene Advances Its Innovative Immunotherapy Pipeline and Extends Financial Visibility Until the End of 2024 (Businesswire)
14.09.23	Transgene Announces Upcoming Investor Meetings (Businesswire)
17.07.23	Transgene Receives $15.3 Million from the Sale of Securities Held for Sale (Businesswire)
06.06.23	Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023 (Businesswire)
05.06.23	Transgene Presents Immunological Data Demonstrating that TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023 (Businesswire)
25.05.23	Transgene and BioInvent Report Positive Phase Ia Data on Oncolytic Virus BT-001 in Solid Tumors (Businesswire)
10.05.23	Transgene provides business update and Q1 2023 financial position (Businesswire)
10.05.23	Transgene - First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administered Intravenously, in Non-Small Cell Lung Cancer (Businesswire)
05.05.23	Transgene’s Combined General Meeting of May 5, 2023 (Businesswire)
05.05.23	Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio (Businesswire)
18.04.23	New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023 (Businesswire)
17.04.23	Transgene - Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR (Businesswire)
12.04.23	Transgene’s Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director (Businesswire)
11.04.23	Transgene: Availability of Preparatory Documents for the Combined General Meeting of May 5, 2023 (Businesswire)
04.04.23	Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers (Businesswire)
27.03.23	Transgene Announces Upcoming Investor Meetings (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Transgene S.A.

Aktien Top/Flop

Meistgelesene Nachrichten